Officinae Bio Srl
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Officinae Bio Srl - overview
Established
2020
Location
Venice, -, Italy
Primary Industry
Biotechnology
About
Founded in 2020 and based in Venice, Italy, Officinae Bio Srl operates as a developer of therapeutic research platforms for cell, gene, and RNA therapy development. In August 2024, Maravai LifeSciences Holdings, Inc. , a portfolio company of GTCR, agreed to acquire Officinae Bio Srl's DNA and RNA Business. Officinae Bio specializes in designing and manufacturing advanced genetic constructs and variant libraries for the cell and gene therapy (CGT) industry.
Their offerings include smart variant libraries, DNA vector engineering, programmable therapies, UTR design, plasmid DNA synthesis, Poly A length precision, and in vitro RNA transcription. Serving biotechnology companies, academic researchers, and pharmaceutical enterprises, Officinae Bio supports genetic engineering and synthetic biology advancements across North America, Europe, and Asia. The company positions itself as a leading platform for biological material solutions, aiming to meet industry needs with sophisticated offerings. Officinae Bio is currently focusing on launching new products designed for enhanced gene therapy applications, with several releases expected in the upcoming year.
The company is targeting expansion into the Asia-Pacific region by the end of 2024.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Bioinformatics
Website
www.officinae.bio
Total Amount Raised
Subscriber access only
Officinae Bio Srl - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out | Completed | Officinae Bio's DNA and RNA Business | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.